Cipla Q1FY25 results: Drugmaker to focus on branded and emerging market expansions; Open to new M&A opportunities – The Financial Express

Cipla recently reported its Q1FY25 results, revealing plans to concentrate on expanding its branded and emerging market presence. The drugmaker is also open to exploring new merger and acquisition opportunities. These strategic moves align with Cipla’s goal of strengthening its position in the pharmaceutical industry.